Results 71 to 80 of about 268,751 (268)
Polish Journal of Pathology, 2017 Multiple primary neoplasms may also occur synchronously. Lymphoma may coexist with second malignant tumor in its primary location or malignant tumor may metastases to lymphomatous lymph nodes.
Anna Szumera-Ciećkiewicz +2 more
doaj +1 more source
Role of Frailty in Assessing Eligibility for CAR T‐Cell Therapy in Haematology
European Journal of Haematology, EarlyView.ABSTRACT Background and Objectives Frailty is a key consideration in determining whether a patient is robust enough for CAR T‐cell therapy; however, it should not represent a barrier to treatment. Our study aimed to describe the extent of research concerning frailty in haematology adult and paediatric patients being considered for CAR T‐cell therapy ...
Jennifer Clesham +4 more
wiley +1 more source
Two cases of systemic mantle cell lymphoma involving the skin
Indian Dermatology Online Journal, 2016 Mantle cell lymphoma (MCL) is a form of non-Hodgkin lymphoma that rarely affects skin. Cutaneous involvement is non-specific but usually indicates widespread disease. Herein we present two cases of MCL with secondary skin involvement.
Viktoryia Kazlouskaya +2 more
doaj +1 more source
Mantle cell lymphoma of the colon [PDF]
Endoscopy, 2014 An 81-year-old man with a history of stage IV mantle cell lymphoma (MCL) diagnosed from a submental lymph node biopsy in 2006 was evaluated for new-onset melena and blood clots with bowel movements. He had been treated for his MCL with 6 cycles of CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab) in 2006, followed by 13 ...
Hazem T. Hammad +3 more
openaire +2 more sources
Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!
Blood, 2018 Blastoid mantle cell lymphoma is characterized by highly aggressive features and a dismal clinical course. These blastoid and pleomorphic variants are defined by cytomorphological features, but the criteria are somewhat subjective.
M. Dreyling, W. Klapper, S. Rule
semanticscholar +1 more source
European Journal of Haematology, EarlyView.ABSTRACT Background/Objectives Bruton tyrosine kinase inhibitors (BTKis) have revolutionized treatment for chronic lymphocytic leukemia (CLL), but cardiovascular (CV) toxicities pose significant challenges. Second‐generation BTKis offer improved target specificity, yet CV risks persist.
Stefano Oliva, Stefano Molica
wiley +1 more source
Mantle cell lymphoma negative for t(11,14) involving the kidneys: a case report
Journal of Medical Case Reports, 2022 Background Mantle cell lymphoma is the rarest subtype of non-Hodgkin’s lymphoma. It can exhibit diverse extranodal manifestations. However, renal involvement is uncommon, and if it occurs, it usually only gets detected postmortem.
Hasan Nassereldine +5 more
doaj +1 more source
European Journal of Haematology, EarlyView.ABSTRACT Primary cutaneous B‐cell lymphomas (CBCL) represent a clinically and biologically heterogeneous group of extranodal non‐Hodgkin lymphomas confined to the skin at the time of diagnosis. They account for approximately 25% of all primary cutaneous lymphomas and are subclassified into distinct entities according to the World Health Organization ...
A. Bernardelli +5 more
wiley +1 more source
Ubiquitination dynamics in human tumour viruses: Viral infection, oncogenesis and antiviral therapy
The FEBS Journal, EarlyView.The ubiquitin system is essential for cellular homeostasis and regulates many processes. Viruses, including oncogenic ones, exploit or evade this system to survive and replicate. This review explores how human tumour viruses manipulate the ubiquitination system to complete their life cycle, evade immunity and promote cancer.
Oscar Trejo‐Cerro +2 more
wiley +1 more source
eJHaem, Volume 6, Issue 6, December 2025.ABSTRACT Introduction Chimeric antigen receptor T‐cell (CART) therapy has shown clinical efficacy in relapsed and refractory large B‐cell malignancies. There is emerging data on the long‐term complications including risk of secondary malignancies. We aimed to describe the incidence and characteristics of secondary malignancies following CART therapy ...
Joanne Britto +9 more
wiley +1 more source